Form 4: Bio-Rad Laboratories Director Allison Schwartz Reports Stock Transactions

Director Allison Schwartz reports acquisition and disposal of Bio-Rad Laboratories Class A common stock related to vesting of restricted stock units.

Summary

• On September 4, 2024, Allison Schwartz, a director of Bio-Rad Laboratories, filed a Form 4 detailing changes in beneficial ownership.
• The report covers transactions from September 1, 2024, to September 3, 2024.
• Schwartz acquired shares of Bio-Rad Class A common stock through the vesting of restricted stock units.
• Simultaneously, shares were disposed of to cover tax obligations related to the vesting of these units.
• The transactions involved multiple vesting dates and corresponding tax-related disposals.
• After the reported transactions, Schwartz directly owns 1,305 shares of Bio-Rad A Common Stock.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to insider transactions, and it doesn't inherently indicate positive or negative sentiment. It reflects the standard compensation practices of the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Monitoring insider transactions is a standard practice in corporate governance.
• Companies like Danaher, Agilent, and Thermo Fisher Scientific, which are Bio-Rad's competitors, also have similar insider transaction reporting requirements.
• The vesting schedules and tax-related disposals are typical for restricted stock unit grants.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• The filing provides transparency to shareholders regarding insider transactions.

Key Dates